A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases

作者：Lee Richard J^*; Saylor Philip J; Michaelson M Dror; Rothenberg S Michael; Smas Malgorzata E; Miyamoto David T; Gurski Carol A; Xie Wanling; Maheswaran Shyamala; Haber Daniel A; Goldin Jonathan G; Smith Matthew R

来源：Clinical Cancer Research, 2013, 19(11): 3088-3094.

DOI：10.1158/1078-0432.CCR-13-0319

Background: Cabozantinib is an oral MET/VEGFR2 inhibitor. A recent phase II study of cabozantinib (100 mg daily) showed improved bone scans in subjects with metastatic castration-resistant prostate cancer (mCRPC), but adverse events (AE) caused frequent dose reductions. This study was designed to determine the efficacy and tolerability of cabozantinib at lower starting doses.
Experimental Design: An adaptive design was used to determine the lowest active daily dose among 60, 40, and 20 mg. The primary endpoint was week 6 bone scan response, defined as >= 30% decrease in bone scan lesion area. The secondary endpoint was change in circulating tumor cells (CTC).
Results: Among 11 evaluable subjects enrolled at 40 mg, there were 9 partial responses (PR), 1 complete response, and 1 stable disease (SD). Of 10 subjects subsequently enrolled at 20 mg, there were 1 PR, 5 SDs, and 4 with progressive disease. Among 13 subjects enrolled on the 40mgexpansion cohort, there were 6 PRs and 7 SDs. No subjects required dose reduction or treatment interruption at 6 or 12 weeks; 3 subjects at dose level 0 discontinued due to AEs by 12 weeks. At 40 mg, median treatment duration was 27 weeks. 58% of subjects with >= 5 CTCs/7.5mL at baseline converted to <5.
Conclusions: Cabozantinib 40 mg daily was associated with a high rate of bone scan response. Cabozantinib 40 mg daily was associated with better tolerability than previously reported for cabozantinib 100 mg daily. These observations informed the design of phase III studies of cabozantinib in mCRPC.

• 出版日期2013-6-1